AYTU Aytu BioPharma, Inc.
Legal ·
Aytu (Nasdaq: AYTU) is the plaintiff against Granules Pharmaceuticals in Delaware, with trial moved to January 12, 2027. It is also a nominal plaintiff in a Section 16(b) suit against Armistice, now on appeal.
Amendment No. 6 to Aytu's loan and security agreement moves both maturities to June 12, 2029 and raises the term loan principal to $13.0 million. The new advance carries SOFR plus 5.50%.
Aytu paid Fabre-Kramer a $3,000,000 upfront on June 5, 2025 for U.S. rights to EXXUA and owes a second $3,000,000 tied to sales timing. Royalties start at 28% of net sales, and the annual report shows an accumulated deficit of $320.0 million.
Aytu agreed to pay a $3,000,000 upfront for U.S. rights to EXXUA, with further payments and royalties of 28% to 39% of net sales that depend on sales.
Aytu BioPharma, Inc. is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases. Its main focus is EXXUA (gepirone) extended-release tablets, which it commercializes in the United States under an Exclusive Commercialization Agreement with Fabre-Kramer Holdings, Inc. entered into in June 2025. The text describes EXXUA as a novel first-in-class selective serotonin 5HT1a receptor agonist approved by the FDA for major depressive disorder in adults. Aytu also sells a prescription ADHD portfolio, Adzenys XR-ODT and Cotempla XR-ODT, and the Pediatric Portfolio product Karbinal ER. Its products are sold primarily through third-party wholesalers and pharmacies. The company has indefinitely suspended active development of its clinical programs, including AR101 (enzastaurin), and wound down and divested its Consumer Health business.
| Product or program | What it is | Stage |
|---|---|---|
| EXXUA (gepirone) extended-release tablets | Treatment of major depressive disorder in adults, commercialized in the United States | approved by the FDA |
| Adzenys XR-ODT and Cotempla XR-ODT | ADHD extended-release orally disintegrating tablets with authorized generic equivalents | sold through third-party wholesalers and pharmacies |
| Karbinal ER | Extended-release carbinoxamine oral suspension for numerous allergic conditions | sold through third-party wholesalers and pharmacies |
| AR101 (enzastaurin) | Clinical program for which active development is indefinitely suspended | development suspended |
| Line | FY ended Jun 30, 2026 | FY ended Jun 30, 2025 |
|---|---|---|
| Research and development | $0 | $1.3 million |
| Net income (loss) | -$14.3 million | -$13.6 million |
| Cash from operations | $3.3 million | -$1.9 million |
| Cash and equivalents | $26.3 million | $31.0 million |
Our latest story on this, dated Sep 22, 2026: "Aytu BioPharma's Adzenys patent suit against Granules heads to a January 2027 trial". The story links the filing or release it is based on. Read the story.
Aytu BioPharma, Inc. trades under the ticker AYTU on NASDAQ.
Aytu BioPharma, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Aytu BioPharma, Inc. is 1385818. Its filings are on SEC EDGAR.
10,866,708 shares as of 2026-09-15, per the cover page of its 10-K filed 2026-09-22.
Our directory records Aytu BioPharma, Inc. under United States.
Our directory classifies Aytu BioPharma, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Aytu BioPharma, Inc. is US0547548588.
aibio.space lists Aytu BioPharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Aytu BioPharma, Inc. is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases. Its main focus is EXXUA (gepirone) extended-release tablets, which it commercializes in the United States under an Exclusive Commercialization Agreement with Fabre-Kramer Holdings, Inc. entered into in June 2025.
EXXUA (gepirone) extended-release tablets: Treatment of major depressive disorder in adults, commercialized in the United States Stage: approved by the FDA.
Adzenys XR-ODT and Cotempla XR-ODT: ADHD extended-release orally disintegrating tablets with authorized generic equivalents Stage: sold through third-party wholesalers and pharmacies.
Aytu BioPharma, Inc. reported a net loss of $14.3 million for the fiscal year ended Jun 30, 2026, and generated $3.3 million of cash from operations, per its annual report to the SEC.
$0 in the fiscal year ended Jun 30, 2026, per its annual report.
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.02,3.02,3.03,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,7.01,9.01). Source
Filed a final prospectus for a securities offering. SEC Form S-1. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio